SI-BONE, Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: SI-BONE, Inc. (Nasdaq: SIBN)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: SI-BONE is a medical device company specializing in minimally invasive surgical implant systems for sacroiliac joint dysfunction, adult spinal deformity, and pelvic trauma. The company markets its iFuse family of products (including iFuse-3D, iFuse TORQ, iFuse Bedrock Granite, and iFuse INTRA) primarily in the United States and 38 other countries. As of December 31, 2024, over 115,000 procedures have been performed using its products.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $167,178 | $138,886 |
| Gross Profit | $132,121 | $109,420 |
| Gross Margin | 79% | 79% |
| Net Loss | $(30,913) | $(43,336) |
| Operating Loss | $(35,248) | $(46,931) |
| Cash and Marketable Securities | $150,042 | $166,019 |
| Long-Term Debt (Principal) | $36,000 | $36,000 |
| Accumulated Deficit | $(431,354) | $(400,441) |
Liquidity: The company had cash and marketable securities of approximately $150.0 million as of December 31, 2024. Management believes existing resources are sufficient to fund operations for the next 12 months and beyond.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% year-over-year to $167.2 million, driven by a $27.8 million increase in U.S. revenue due to expanded product portfolio and growing physician base, and a $0.5 million increase in international revenue.
- Profitability: Net loss improved by $12.4 million (29% reduction) to $30.9 million, primarily due to increased revenue and a reduction in depreciation expense following a change in the estimated useful life of instrument trays.
- Operating Expenses: Total operating expenses increased 7% to $167.4 million. Sales and marketing expenses rose 6% due to higher commissions and physician training costs. R&D expenses increased 10% due to higher headcount and product development costs.
- Debt Refinancing: In November 2024, the company entered into a Third Amendment to its Loan and Security Agreement, refinancing its term loan with a maturity date extended to September 1, 2029.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategy: Management continues to focus on expanding the sales force, increasing physician engagement, and launching new products (iFuse INTRA and iFuse TORQ TNT). The company anticipates continued investment in R&D and commercial infrastructure, expecting to incur operating losses in the future as it scales.
Key Risks:
- Reimbursement Uncertainty: Significant risk exists regarding coverage and reimbursement policies, particularly for CPT Code 27278 (intra-articular implants) where some Medicare Administrative Contractors have precluded coverage. Pricing pressure is acute in Ambulatory Surgical Centers (ASCs) and Office-Based Labs (OBLs).
- Regulatory and Legal: In October 2024, the company received a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding an investigation under the Anti-Kickback Statute and False Claims Act concerning meals and consulting payments to healthcare professionals. The outcome is uncertain and could result in significant penalties.
- Supply Chain: The company relies on a limited number of third-party suppliers, including a single-source supplier (RMS) for key implants. Disruptions could materially impact operations.
- Patent Expirations: U.S. patents on the first-generation iFuse triangular shape expire in December 2025, potentially allowing competitors to market similar devices.
Investor Verification Checklist
- DOJ Investigation Status: Monitor updates regarding the Civil Investigative Demand (CID) received in October 2024 and potential financial or operational impacts.
- Reimbursement Trends: Verify the status of Medicare coverage for CPT Code 27278 and the impact of the new Transitional Pass-Through (TPT) payment for iFuse Bedrock Granite in outpatient settings (effective Jan 1, 2025).
- Cash Burn Rate: Assess the sustainability of the current cash position ($150M) against the trajectory of operating losses and capital expenditure requirements for new product launches.
- Patent Cliff: Evaluate the competitive landscape and potential revenue impact as the core iFuse patent expires in late 2025.
- Debt Covenants: Review the financial covenants in the Third Amended Loan Agreement to ensure compliance and understand restrictions on future financing or dividends.